Archive · 25 Sep 2025
Indian Market Dips, Pharma Index Falls Amid Mixed Views
The Indian stock market fell on September 25, 2025.
The Nifty 50 and Sensex indices closed lower.
Pharma stocks, like Cipla and Dr. Reddy's, declined.
Glenmark Pharma, however, rose due to a licensing deal.
Investors lost a lot of money.
Some analysts are optimistic about certain pharma companies, while others are cautious.
Despite the recent downturn, the pharma index has shown strong returns over the last three years.
Indian stock market closed with significant losses for the fifth straight session.
The Sensex and Nifty 50 both declined on September 25, 2025.
The Nifty Pharma index fell by 0.75% with most stocks declining.
Glenmark Pharma was a top gainer, up 1.03%, following a licensing agreement.
Analysts hold mixed views on pharma stocks, reflected in their ratings.
- Who
- Indian stock market investors and analysts
- What
- The Indian stock market experienced a decline, particularly in the Pharma sector.
- When
- September 25, 2025
- Where
- Indian Stock Market
- Why
- Weak global cues and mixed analyst views affected market performance.
Market Sentiment
Analyst Perspectives
Overall Market View
Market Sentiment
The broader market experienced significant losses, indicated by the decline in the Sensex and Nifty 50.
Analyst Perspectives
Analysts hold mixed views with some recommending buy and overweight ratings, while others are neutral, reflecting varying confidence levels across the sector.
- Nifty 50 Close
- 24,890.85
- Sensex Close
- 81,159.68
- Nifty Pharma Index Change
- -0.75%
- Market Cap Loss
- ₹3 lakh crore
- Glenmark Pharma Gain
- 1.03%
- Nifty Pharma Three-Year Return
- 74.58%
Sources
Glenmark Pharma arm enters $1.1 billion agreement with Hengrui for oncology drug
Glenmark Pharma secures paid license for Hengrui’s trastuzumab rezetecan cancer drug
Glenmark inks exclusive licensing pact with Hengrui for next-gen cancer drug; to make $18 m upfront payment
Glenmark inks $18 million deal for cancer drug with China’s Hengrui
More pain ahead for Glenmark Pharma? 3 reasons why Nomura sees 25% downside after licencing deal for cancer drug
Nifty Pharma falls 0.75% as most stocks decline amid mixed analyst views